Phase 3 Recruiting Network
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medicat…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05929768
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Main Campus — Crown Point, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Main Campus — Crown Point, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Sites in Indiana: - IU Health West Hospital — Avon, Indiana
- IU Health North Hospital — Carmel, Indiana
- Northwest Cancer Center - Crown Point — Crown Point, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Indiana: - Northwest Cancer Center - Crown Point — Crown Point, Indiana
- UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Goshen Center for Cancer Care — Goshen, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
Phase 3 Recruiting Industry
The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surgery, is effective and safe compared to the treatment of physician's choice (TPC) which inc…
Sponsor: Gilead Sciences
NCT ID: NCT05633654
Sites in Indiana: - Franciscan Health Indianapolis — Indianapolis, Indiana
- Investigative Clinical Research of Indiana, LLC — Indianapolis, Indiana
- IU Health Arnett Hospital — Lafayette, Indiana
- Franciscan Health Munster — Munster, Indiana
Phase 3 Recruiting Industry
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early b…
Sponsor: Stemline Therapeutics, Inc.
NCT ID: NCT06492616
Sites in Indiana: - Northwest Cancer Centers, PC — Dyer, Indiana
Phase 3 Recruiting Industry
The purpose of this open-label, multicenter, phase IIIb, single-arm study is to characterize the efficacy and safety of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive breast cancer-free survival (iBC…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05827081
Sites in Indiana: - Investigative Clinical R of Indiana — Indianapolis, Indiana
Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizuma…
Sponsor: AstraZeneca
NCT ID: NCT06103864
Sites in Indiana: - Research Site — New Albany, Indiana
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat types of breast cancer that are both: * High-risk, which means the cancer may have a higher chance of getting worse or coming back after treatment * Early-stage, which means the cancer is in th…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06966700
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology ( Site 0084) — Fort Wayne, Indiana
- Franciscan Health ( Site 0077) — Indianapolis, Indiana
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Indiana: - UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Woodland Cancer Care Center — Michigan City, Indiana
- Reid Health — Richmond, Indiana
- Memorial Hospital of South Bend — South Bend, Indiana
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.
Sponsor: Oana Danciu
NCT ID: NCT05467891
Sites in Indiana: - Parkview Research Center — Fort Wayne, Indiana
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Sponsor: Volastra Therapeutics, Inc.
NCT ID: NCT05902988
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This is a randomized Phase II study of standard of care (SOC) chemotherapy monotherapy vs. SOC chemotherapy combined with tocilizumab in in Black and non-Black patients with metastatic triple negative or ER low breast cancer.
Sponsor: Kathy Miller
NCT ID: NCT05846789
Sites in Indiana: - IU Health Joe and Shelly Schwarz Cancer Center — Carmel, Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
This study is a Phase 1/2, first-in-human, open-label, clinical trial to assess the safety, tolerability, pharmacokinetics and preliminary efficacy of HMBD-501 in patients with advanced-stage, relapsed and/or refractory human epidermal gro…
Sponsor: Hummingbird Bioscience
NCT ID: NCT06956690
Sites in Indiana: - Research Site — Indianapolis, Indiana
Phase 1 Recruiting Academic/Other
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immun…
Sponsor: Pravin T.P Kaumaya
NCT ID: NCT06414733
Sites in Indiana: - Indiana University Melvin & Bren Simon Comprehensive Cancer Center — Indianpolis, Indiana
Phase 1 Recruiting Academic/Other
The goal of this study is to test an investigational vaccine to activate the immune system to fight breast cancer.
Sponsor: Pravin T.P Kaumaya
NCT ID: NCT06949410
Sites in Indiana: - Indiana University Melvin & Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Indiana: - Woodland Cancer Care Center — Michigan City, Indiana
- Reid Health — Richmond, Indiana
NA Recruiting Academic/Other
Germline testing for hereditary cancer syndromes is underutilized across most health care settings. Using a learning health care approach, the Genomics-enabled Learning Health Systems (gLHS) network aims to evaluate the impact of a suite o…
Sponsor: Josh Peterson
NCT ID: NCT07307664
Sites in Indiana: - Indiana University School of Medicine — Indianapolis, Indiana
NA Recruiting Academic/Other
The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team hypothesizes that delivering virtual, su…
Sponsor: Indiana University
NCT ID: NCT05468034
Sites in Indiana: - IU Health West — Avon, Indiana
- IU Health Joe and Shelly Schwarz Cancer Center — Carmel, Indiana
- Indiana University Melvin & Bren Simon Cancer Center — Indianapolis, Indiana
- Sidney and Lois Eskenazi Hospital — Indianapolis, Indiana
NA Recruiting Academic/Other
The purpose of this study is to assess the feasibility of the NearWave optical molecular monitoring system for monitoring therapy progression and predicting pathologic complete response (pCR) of breast cancer patients undergoing neoadjuvan…
Sponsor: Indiana University
NCT ID: NCT06744465
Sites in Indiana: - Indiana University Simon Comprehensive Cancer Center — Indianapolis, Indiana